search

Active clinical trials for "Breast Neoplasms"

Results 2011-2020 of 10251

Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients

Breast Neoplasms

In nonmetastatic local advanced breast cancer patients, we are going to investigate whether circulating tumor DNA (ctDNA) detection can reflect the tumor response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery.

Recruiting11 enrollment criteria

A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant...

Breast Cancer

This research study is evaluating whether the use of digital breast tomosynthesis and near-infrared tomographic optical breast imaging (DBT-TOBI) scans can predict the response of triple negative or HER2+ breast cancer to neoadjuvant chemotherapy. The study radiologic scan involved in this study is digital breast tomosynthesis (also called 3 Dimensional mammogram) combined with near-infrared tomographic optical breast imaging, or DBT-TOBI.

Active21 enrollment criteria

MACSSI (MAstectomie Cellules Souches Surveillance Immunitaire)

Breast Cancer

Monocentric, observational and prospective study in adult women having an early-stage breast cancer without genetic risk. The main objective is to characterize quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland in women: With a moderate risk of breast cancer progression (women with an early "Luminal A" tumor) = Group A. With a high risk of breast cancer progression (women with an early "Luminal B" or basal tumor) = Group B.

Recruiting14 enrollment criteria

Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer

Breast Cancer

PELICAN is a randomised phase II trial that aims to evaluate the efficacy and safety of paclitaxel plus pembrolizumab relative to paclitaxel alone, in patients with locally advanced or metastatic ER-positive, HER2-negative, Luminal B breast cancer who have received no prior chemotherapy for advanced or metastatic disease. Patients will be randomised (2:1) to one of the two treatment arms: Pembrolizumab plus Paclitaxel Paclitaxel

Not yet recruiting46 enrollment criteria

Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v814 more

This is a pilot study to determine safety, efficacy, and potential risks of robot assisted nipple sparing mastectomy (RNSM), by utilizing the daVinci surgical system.

Active18 enrollment criteria

Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive...

Breast CancerNeoadjuvant Therapy1 more

Today, the majority of clinically node positive (cN+) breast cancer patients is treated with neoadjuvant systemic therapy (NST). Axillary staging and treatment after NST in cN+ patients are areas of controversy. Patients with a pathological complete response (pCR) of the axillary lymph nodes are not expected to benefit from axillary lymph node dissection (ALND). Hence, less invasive axillary staging procedures are being introduced to avoid unnecessary ALND. However, evidence supporting the safety of replacing ALND by less invasive techniques in terms of oncologic safety and impact on quality of life (QoL) is lacking.

Recruiting10 enrollment criteria

Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple...

Triple Negative Breast Cancer

The INSTIGO study aims to assess a plasma protein profile at different stages of patient follow-up as a predictive factor of metastatic recurrence in triple negative breast cancer. It also aims to look at other potential biomarkers of metastatic relapse such as Tumor-infiltrating Lymphocytes, circulating tumor DNA, figurative elements in blood, or a tumor RNA signature.

Recruiting8 enrollment criteria

Early Detection of CMP in Patients With Breast Cancer Using Cardiac Magnetic Resonance

Breast CancerChemotherapy Induced Systolic Dysfunction

Breast cancer is the most common cancers among women worldwide.Although chemotherapy and surgery have greatly improved the survival rate, most types of chemotherapy have been reported to have varying degrees of cardiotoxicity. The investigators will focus on the cardiotoxicity of pyrotinib and apatinib which belong to the new tyrosine kinase inhibitors in respective chemotherapy among more subjects.

Recruiting15 enrollment criteria

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+...

HER2+ Early or Locally Advanced Breast Cancer

The study is being conducted to evaluate the efficacy, and safety of pyrotinib versus pertuzumab in combination with trastuzumab and nab-paclitaxel for neoadjuvant treatment in HER2+ early or locally advanced breast cancer patients. To explore whether pyrotinib regimen could provide better clinical results compared with pertuzumab in the study population.

Not yet recruiting21 enrollment criteria

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring

Breast CarcinomaBreast Neoplasm

This study evaluates the effectiveness of a breast ultrasound method for the diagnosis of breast cancer. Diagnostic procedures, such as breast ultrasound, may help find and diagnose breast cancer, and may help measure a patient's response to earlier treatment. The purpose of this research is to test the effectiveness of a new investigational breast ultrasound method to detect an abnormality in the breast, and assess response to breast cancer treatment.

Recruiting3 enrollment criteria
1...201202203...1026

Need Help? Contact our team!


We'll reach out to this number within 24 hrs